TRIM24
TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.
Overview
Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity.
Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes affected pathway 0.96, literature 0.98, genetic association 0.44, somatic mutation 0.83, animal model 0.71). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.
- 1 · What it is
TRIM24 (Transcription intermediary factor 1-alpha) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Prostate cancer, Lung cancer and 3 more.
- 2 · What goes wrong in cancer
Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes.
- 3 · How drugs use it
No product in this corpus aims at TRIM24 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:11812 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15164 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000122779 (association with cancer (MONDO_0004992) 0.79; per-cancer scores at or above 0.5: ovarian cancer 0.51, non-Hodgkin lymphoma 0.51, breast cancer 0.53, lung cancer 0.53, leukaemia 0.60 (GraphQL API, CC0)); IntOGen TRIM24 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional coactivator that interacts with numerous nuclear receptors and coactivators and modulates the transcription of target genes. Interacts with chromatin depending on histone H3 modifications, having the highest affinity for histone H3 that is both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has E3 protein-ubiquitin ligase activity. During the DNA damage response, participates in an autoregulatory feedback loop with TP53. Early in response to DNA damage, ATM kinase phosphorylates TRIM24 leading to its ubiquitination and degradation. After sufficient DNA repair has occurred, TP53 activates TRIM24 transcription, ultimately leading to TRIM24-mediated TP53 ubiquitination and degradation. Location: Nucleus; Cytoplasm; Mitochondrion (UniProt). Locus 7q33-q34 (HGNC).
- Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Breast cancer: Open Targets association 0.53 with breast cancer (MONDO_0007254)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170)
- Non-Hodgkin lymphoma: Open Targets association 0.51 with non-Hodgkin lymphoma (MONDO_0018908)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TRIM24" OR ABSTRACT:"TRIM24" OR TITLE:"tripartite motif containing 24" OR ABSTRACT:"tripartite motif containing 24" OR TITLE:"Transcription intermediary factor 1-alpha" OR ABSTRACT:"Transcription intermediary factor 1-alpha" OR TITLE:"hTIF1" OR ABSTRACT:"hTIF1" OR TITLE:"Tif1a" OR ABSTRACT:"Tif1a" OR TITLE:"RNF82" OR ABSTRACT:"RNF82") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TRIM24, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetEPS15
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types), IntOGen.
- TargetRUNX1T1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetSND1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetPOLD1
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetPAX5
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetMLLT10
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types), Ovarian cancer.
- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Prostate cancer.
- TargetPOLA2
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).